Last updated: March 2026
Pinealon (Glu-Asp-Arg / EDR) is a synthetic tripeptide from Vladimir Khavinson's bioregulatory peptide family. It crosses the blood-brain barrier, enters cell nuclei, and modulates gene transcription linked to serotonin release, melatonin pathways, neuroprotection, and sleep architecture. Developed at Russia's Institute of Bioregulation and Gerontology with 40+ years of research.
Pinealon operates through a fundamentally different mechanism than most neuropeptides. Rather than binding surface receptors, it enters cell nuclei and modulates DNA transcription directly — making it both tissue-specific and epigenetically active.
Unlike most peptides that bind surface receptors, Pinealon (EDR) penetrates cell nuclei and directly interacts with DNA regulatory sequences. It binds to specific promoter regions, modulating transcription of genes involved in neuroprotection, neuronal metabolism, and circadian rhythm control. This epigenetic mechanism is the defining feature of Khavinson's bioregulator class — tissue specificity achieved through gene-level interaction rather than receptor selectivity.
At just three amino acids, Pinealon's molecular weight (~400 Da) allows passive diffusion across the blood-brain barrier and active transport via peptide transporter systems (PEPT1/PEPT2). This is a critical pharmacological advantage: most neuroprotective agents fail in clinical trials primarily because they cannot achieve adequate CNS penetration. Pinealon's small size solves this problem intrinsically. Intranasal delivery further bypasses the BBB entirely via the olfactory pathway.
Khavinson's 2014 study (Bulletin of Experimental Biology and Medicine) directly demonstrated that Pinealon stimulates serotonin release in brain tissue preparations. Since melatonin biosynthesis depends on serotonin as a precursor (serotonin → N-acetylserotonin → melatonin), Pinealon's upstream serotonergic effect supports the entire melatonin synthesis pathway. This explains the documented improvements in sleep architecture — particularly REM duration and deep sleep consolidation — observed in clinical applications.
Under hypoxic (low-oxygen) conditions — as occur in TBI, stroke, or ischemic events — Pinealon upregulates the expression of antiapoptotic genes including Bcl-2 family members, protecting neurons from oxidative stress-induced cell death. Animal studies showed significant reduction in cortical neuron apoptosis following ischemia-reperfusion injury. This protective effect persists beyond the peptide's active half-life, suggesting durable gene expression changes rather than transient receptor activation.
Pinealon modulates transcription of genes involved in mitochondrial function and neuronal energy metabolism. By improving mitochondrial efficiency in neurons, it supports sustained cognitive performance, particularly under conditions of metabolic stress such as aging, sleep deprivation, or poor cerebral circulation. This metabolic optimization complements its direct neuroprotective effects.
Pinealon directly targets brain cortex gene expression related to circadian regulation. While Epithalon restores melatonin secretion from the pineal gland, Pinealon works downstream — modulating how cortical neurons respond to melatonin signals and regulating the expression of clock genes (CLOCK, BMAL1, PER, CRY). This dual-level circadian action makes the Epitalon + Pinealon combination mechanistically synergistic for circadian restoration in aging individuals.
Pinealon belongs to a class of ultra-short peptides (2–4 amino acids) developed over 50 years by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Each bioregulator targets a specific organ or tissue system.
The Bioregulator Concept: Khavinson's hypothesis — validated across dozens of studies — is that aging involves progressive silencing of tissue-specific genes. Short peptides (2–4 aa) can re-activate these genes by binding DNA regulatory sequences, essentially "reminding" aging tissues of their youthful gene expression patterns. Over 15 million patients have been treated with bioregulators in Russia and Eastern Europe.
Epithalon vs. Pinealon — Critical Distinction: Both target the sleep-melatonin system but at different levels. Epithalon works at the pineal gland itself — restoring the gland's capacity to produce melatonin and activating telomerase. Pinealon works downstream in brain cortex cells — modulating serotonin (melatonin precursor) and how cortical neurons express circadian genes. The two are mechanistically complementary, which is why Khavinson's clinical protocols often combine them.
Pinealon's research base is primarily Russian — predominantly from Khavinson's institute and affiliated researchers. The evidence is consistent but lacks large-scale Western replication. Context: over 15 million patients treated with Khavinson bioregulators overall.
Data Transparency: Pinealon's trials are predominantly Russian-origin, single-center studies. Most lack placebo-controlled Western replication. The mechanism is scientifically plausible and consistent across multiple papers, but these limitations must be acknowledged. Treat this as promising research-stage evidence — not established clinical consensus.
Pinealon has two primary application areas with overlapping mechanisms. Understanding which you're targeting shapes how you time and dose it.
Core use case: preserving and restoring brain function against insults — aging, TBI, ischemia, hypoxia, or neurodegenerative risk. Pinealon's nuclear mechanism means it targets the root cause of age-related neuronal decline (gene silencing) rather than symptom management. It's used by Russian clinicians for both acute TBI recovery and preventive brain anti-aging protocols. Upregulates Bcl-2, reduces oxidative stress markers in neurons, and preserves synaptic density.
Via serotonin → melatonin pathway modulation, Pinealon improves both sleep onset and sleep quality — particularly REM and slow-wave sleep duration. Unlike melatonin supplements (which spike and crash), Pinealon modulates the upstream synthesis pathway, enabling more natural, regulated melatonin production. Particularly valuable for shift workers, aging individuals with circadian disruption, and those with post-TBI sleep dysfunction. Combines well with DSIP for deeper slow-wave sleep synergy.
As part of a longevity protocol, Pinealon addresses the brain component of systemic aging. Better sleep architecture → better memory consolidation. Neuroprotection → slower cognitive decline. Serotonin modulation → improved mood stability and motivation. In Khavinson's longevity protocols, Pinealon is used alongside Epithalon to comprehensively address both cellular aging (telomerase) and brain-specific aging (cortical gene silencing).
The TBI trial data is the strongest clinical evidence for Pinealon's use in acute neurological injury. Russian hospitals use it in post-stroke and post-TBI rehabilitation protocols. The mechanism — upregulating neuroprotective genes and reducing post-ischemic apoptosis — is consistent with known recovery biology. Not a replacement for standard neurorehabilitation, but a potentially powerful adjunct that addresses the molecular biology of recovery.
Pinealon has a notable advantage over most research peptides: it can be taken orally. Its tripeptide size allows gastric survival and intestinal absorption, validated in Russian clinical research.
| Protocol | Route | Dose Per Administration | Frequency | Cycle Length |
|---|---|---|---|---|
| Conservative Start | Oral | 5–10 mg | Once daily (morning) | 10 days on, then assess |
| Standard Oral | Oral | 10–20 mg/day | Split BID (morning + night) | 10–30 days, 2–4x per year |
| Intranasal — Standard | Intranasal spray | 100–200 mcg per nostril | Once daily (before bed) | 10–20 days per cycle |
| Intranasal — Sleep Focus | Intranasal | 200 mcg per nostril × 1 | 30–60 min before sleep | 2–3 weeks, evaluate |
| Khavinson Full Stack | Oral/SubQ | Pinealon + Epithalon combined | Per Russian longevity protocol | Spring + Fall cycles annually |
| Acute Neuroprotection (TBI) | Oral or SubQ | 20 mg/day | Daily for 30 days | 30-day course, repeat if indicated |
Timing matters: For sleep optimization, dose Pinealon in the evening 30–60 minutes before bed to leverage the serotonin → melatonin conversion window. For neuroprotection and cognition, morning dosing is common. For the Khavinson longevity protocol, twice-yearly cycles (spring and fall) are conventional, though daily or near-daily use for therapeutic indications is supported by the TBI data.
Both routes are validated in Russian research. Oral is more convenient, lower cost, and allows sustained tissue-level delivery. Intranasal bypasses the BBB entirely via the olfactory pathway, offering faster onset and potentially higher CNS bioavailability — preferred for sleep applications. Most biohackers use oral for daily protocol use and intranasal for acute or sleep-targeted cycles.
How Pinealon sits relative to other compounds in the sleep and neuroprotection space — to help you understand where it fits in a stack.
⚠️ Cross-compound comparisons come from different studies and populations. Direct head-to-head data does not exist.
| Compound | Primary Target | Sleep Effect | Neuroprotection | BBB Penetration | Oral Bioavail. | Research Depth |
|---|---|---|---|---|---|---|
| Pinealon (EDR) | Brain cortex, serotonin/melatonin | ✅ Architecture improvement | ✅ Strong (TBI data) | ✅ Yes (small tripeptide) | ✅ Yes | ⚠️ Russian-only |
| Epithalon (AEDG) | Pineal gland, telomeres | ✅ Circadian restoration | ✅ Anti-cancer, longevity | ✅ Yes (tetrapeptide) | ⚠️ Limited (usually SubQ) | ✅ Strongest (775+ papers) |
| DSIP | Delta sleep induction | ✅ Deep sleep (SWS) | — Minimal data | ✅ Yes | ❌ SubQ/intranasal preferred | ⚠️ Limited Western |
| Semax | BDNF upregulation, cognition | — Not primary | ✅ Strong (BDNF-driven) | ✅ Intranasal | ❌ Intranasal only | ✅ Solid Russian data |
| Selank | Anxiolytic (GABA-A) | ⚠️ Via anxiety reduction | — Minimal | ✅ Intranasal | ❌ Intranasal only | ✅ Approved Russia 2009 |
| Melatonin (pharma) | MT1/MT2 receptor agonism | ✅ Direct sedation | ⚠️ Antioxidant, limited | ✅ Yes | ✅ Yes | ✅ Extensive Western |
Pinealon has a favorable safety record across Russian clinical research. As a naturally occurring amino acid sequence, it presents a different risk profile than synthetic small molecules.
Pinealon is not for everyone. Its evidence base, mechanism, and risk profile point to specific populations where benefit-to-risk is most favorable.
Pinealon works best in context — alongside related compounds and stacking protocols. Explore these to build a complete picture.
Products relevant to Pinealon use — peptide storage, administration, and sleep optimization tools.
Affiliate links support MeetPeptide at no extra cost to you.
This content is for educational and informational purposes only. Pinealon is a research compound — it is not FDA-approved and is not intended to diagnose, treat, cure, or prevent any disease or medical condition. The research cited is predominantly Russian-origin and lacks Western independent replication. Do not use this information to make medical decisions. Always consult a qualified healthcare provider before starting any peptide or supplement protocol. Peptide purity and safety varies by vendor. MeetPeptide does not endorse any specific product or vendor.